Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy (TUMORNATOR I)

NCT06542757 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT06542757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06542757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Tumor Control Based on Serial Multiparametric MRI and Post-Treatment Biopsies For Patients Treated With Dose Intensification to the Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR-Guided Radiotherapy (TUMORNATOR I)
Lead sponsor
NYU Langone Health
Phase
Not applicable
Overall status
Recruiting
Start date
December 9, 2024
Completion date
December 31, 2029
Enrollment
91 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer